New England Journal of Medicine· 2013Q1

Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients

Alexander T Cohen, Theodore E. Spiro, Harry R. Büller, Lloyd Haskell et al.

604citations
Q1SCImago
2013year

Short summary

Extended-duration oral rivaroxaban (35 days) reduced venous thromboembolism (VTE) risk by 23% compared to standard-duration enoxaparin (10 days) followed by placebo in acutely ill medical patients, though it doubled bleeding risk.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Internal Medicine

Internal MedicineMedicine